table of content
1 Study Coverage
1.1 Hormone Refractory Prostate Cancer Revenue in Hormone Refractory Prostate Cancer Business (2017-2022) & (US$ Million) Introduction
1.2 Global Hormone Refractory Prostate Cancer Outlook 2017 VS 2022 VS 2028
1.2.1 Global Hormone Refractory Prostate Cancer Market Size for the Year 2017-2028
1.2.2 Global Hormone Refractory Prostate Cancer Market Size for the Year 2017-2028
1.3 Hormone Refractory Prostate Cancer Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Hormone Refractory Prostate Cancer in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Hormone Refractory Prostate Cancer Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Hormone Refractory Prostate Cancer Market Dynamics
1.4.1 Hormone Refractory Prostate Cancer Industry Trends
1.4.2 Hormone Refractory Prostate Cancer Market Drivers
1.4.3 Hormone Refractory Prostate Cancer Market Challenges
1.4.4 Hormone Refractory Prostate Cancer Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Hormone Refractory Prostate Cancer by Type
2.1 Hormone Refractory Prostate Cancer Market Segment by Type
2.1.1 Chemotherapy
2.1.2 Hormonal Therapy
2.1.3 Immunotherapy
2.1.4 Radiation Therapy
2.2 Global Hormone Refractory Prostate Cancer Market Size by Type (2017, 2022 & 2028)
2.3 Global Hormone Refractory Prostate Cancer Market Size by Type (2017-2028)
2.4 United States Hormone Refractory Prostate Cancer Market Size by Type (2017, 2022 & 2028)
2.5 United States Hormone Refractory Prostate Cancer Market Size by Type (2017-2028)
3 Hormone Refractory Prostate Cancer by Application
3.1 Hormone Refractory Prostate Cancer Market Segment by Application
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Specialty Clinics
3.2 Global Hormone Refractory Prostate Cancer Market Size by Application (2017, 2022 & 2028)
3.3 Global Hormone Refractory Prostate Cancer Market Size by Application (2017-2028)
3.4 United States Hormone Refractory Prostate Cancer Market Size by Application (2017, 2022 & 2028)
3.5 United States Hormone Refractory Prostate Cancer Market Size by Application (2017-2028)
4 Global Hormone Refractory Prostate Cancer Competitor Landscape by Company
4.1 Global Hormone Refractory Prostate Cancer Market Size by Company
4.1.1 Top Global Hormone Refractory Prostate Cancer Companies Ranked by Revenue (2021)
4.1.2 Global Hormone Refractory Prostate Cancer Revenue by Player (2017-2022)
4.2 Global Hormone Refractory Prostate Cancer Concentration Ratio (CR)
4.2.1 Hormone Refractory Prostate Cancer Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Hormone Refractory Prostate Cancer in 2021
4.2.3 Global Hormone Refractory Prostate Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Hormone Refractory Prostate Cancer Headquarters, Revenue in Hormone Refractory Prostate Cancer Business (2017-2022) & (US$ Million) Type
4.3.1 Global Hormone Refractory Prostate Cancer Headquarters and Area Served
4.3.2 Global Hormone Refractory Prostate Cancer Companies Revenue in Hormone Refractory Prostate Cancer Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Hormone Refractory Prostate Cancer Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Hormone Refractory Prostate Cancer Market Size by Company
4.5.1 Top Hormone Refractory Prostate Cancer Players in United States, Ranked by Revenue (2021)
4.5.2 United States Hormone Refractory Prostate Cancer Revenue by Players (2020, 2021 & 2022)
5 Global Hormone Refractory Prostate Cancer Market Size by Region
5.1 Global Hormone Refractory Prostate Cancer Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Hormone Refractory Prostate Cancer Market Size by Region (2017-2028)
5.2.1 Global Hormone Refractory Prostate Cancer Market Size by Region: 2017-2022
5.2.2 Global Hormone Refractory Prostate Cancer Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Hormone Refractory Prostate Cancer Market Size YoY Growth 2017-2028
6.1.2 North America Hormone Refractory Prostate Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Hormone Refractory Prostate Cancer Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Hormone Refractory Prostate Cancer Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Hormone Refractory Prostate Cancer Market Size YoY Growth 2017-2028
6.3.2 Europe Hormone Refractory Prostate Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Hormone Refractory Prostate Cancer Market Size YoY Growth 2017-2028
6.4.2 Latin America Hormone Refractory Prostate Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Hormone Refractory Prostate Cancer Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Hormone Refractory Prostate Cancer Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Astellas Inc
7.1.1 Astellas Inc Company Details
7.1.2 Astellas Inc Business Overview
7.1.3 Astellas Inc Hormone Refractory Prostate Cancer Introduction
7.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer Business (2017-2022)
7.1.5 Astellas Inc Recent Development
7.2 Sanofi S.A
7.2.1 Sanofi S.A Company Details
7.2.2 Sanofi S.A Business Overview
7.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Introduction
7.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer Business (2017-2022)
7.2.5 Sanofi S.A Recent Development
7.3 Dendreon Corporation, Bayer AG
7.3.1 Dendreon Corporation, Bayer AG Company Details
7.3.2 Dendreon Corporation, Bayer AG Business Overview
7.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Introduction
7.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer Business (2017-2022)
7.3.5 Dendreon Corporation, Bayer AG Recent Development
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Details
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Introduction
7.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer Business (2017-2022)
7.4.5 Johnson & Johnson Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
